NGM Biopharmaceuticals

NGM Biopharmaceuticals
Last activity: 19.03.2024
Categories: ResearchPlatformMedTechMarketInterestHumanHealthTechEngineeringDrugDevelopment
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. All of NGM Bio’s clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM Bio.
Location: United States, California, South San Francisco
Employees: 201-500
Total raised: $101M
Founded date: 2008

Investors 4

Funding Rounds 2

18.07.2013Series C$50M-
15.03.2010Series B$51M-

Mentions in press and media 49

19.03.2024NGM Bio to Present Two Posters Highlighting Clinical Data fr...SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bi...einpresswi...
11.03.2024NGM Bio Provides Recent Business Highlights and Reports Four...--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Pha...einpresswi...
11.03.2024NGM Bio Provides Recent Business Highlights and Reports Four...-globenewsw...
26.02.2024NGM to go private as part of $135M buyout by VC firm Column ...Following a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided t...fiercebiot...
20.02.2024NGM Bio to Participate in the Cowen 44th Annual Health Care ...SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq:...einpresswi...
25.05.2023NGM Bio to Participate in Upcoming Investor Conferences/EIN News/ -- SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, ...einpresswi...
08.05.2023NGM Bio Announces Presentation of Data from Phase 2 Investig...Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid sy...einpresswi...
04.05.2023NGM Bio Reports First Quarter 2023 Financial Results and Pro...Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvem...einpresswi...
25.03.2023Her doctor said her severe morning sickness was all in her h...Taped above a tidy wooden desk in the corner of her bedroom, right at eye level, is a piece of paper...channelnew...
04.11.2022NGM Bio Announces Poster Presentation Featuring Preclinical .../EIN News/ -- --Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting d...einpresswi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In